Our Pricing

Wegovy vs Mounjaro Weight Loss: Which Treatment Works Better?

When comparing Wegovy vs Mounjaro weight loss injections, both GLP-1 receptor agonists offer clinically proven results, but they differ significantly in efficacy, mechanism, and cost. Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors, whilst Wegovy (semaglutide) focuses solely on GLP-1, leading to measurable differences in average weight reduction. Understanding these distinctions helps patients and prescribers select the most appropriate treatment based on individual health profiles and budget considerations.

How Wegovy vs Mounjaro Weight Loss Mechanisms Differ

The fundamental difference between Wegovy vs Mounjaro weight loss treatments lies in their receptor activity. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways [1]. This dual action enhances insulin secretion, reduces glucagon release, and slows gastric emptying more effectively than single-receptor treatments. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that primarily reduces appetite through hypothalamic pathways and delays gastric emptying [2].

In clinical practice, this mechanistic difference translates to varying degrees of appetite suppression and metabolic improvement. Patients on Mounjaro often report earlier and more pronounced satiety signals compared to Wegovy users, though individual responses vary considerably. Both medications require gradual dose escalation over 16-20 weeks to minimise gastrointestinal side effects whilst optimising therapeutic benefit. The dual-receptor mechanism of tirzepatide may offer additional cardiovascular and glycaemic benefits beyond weight reduction, particularly in patients with pre-diabetes or metabolic syndrome [3].

Receptor Binding and Metabolic Pathways

GIP receptors, uniquely targeted by Mounjaro, are predominantly found in pancreatic beta cells and adipose tissue. Activation of these receptors enhances insulin secretion in a glucose-dependent manner whilst potentially improving lipid metabolism and reducing inflammation in fat tissue. The combined GIP/GLP-1 action creates synergistic effects that surpass either pathway alone, explaining the superior weight loss outcomes observed in head-to-head trials. Wegovy's selective GLP-1 activity remains highly effective, with proven cardiovascular benefits demonstrated in the SELECT trial, making it an excellent choice for patients with established heart disease [4].

Clinical Trial Results: Wegovy vs Mounjaro Weight Loss Efficacy

Direct comparison of Wegovy vs Mounjaro weight loss outcomes reveals significant differences in average weight reduction. The SURPASS-2 trial demonstrated that tirzepatide 15mg achieved up to 22.5% total body weight loss over 72 weeks in adults with obesity, compared to 6.7% with semaglutide 1mg [1]. However, when comparing maximum doses—tirzepatide 15mg versus semaglutide 2.4mg (Wegovy dose)—the gap narrows but remains clinically meaningful, with tirzepatide showing approximately 5-7% greater average weight loss in indirect comparisons.

The STEP programme trials for Wegovy demonstrated average weight loss of 14.9% over 68 weeks at the 2.4mg maintenance dose, with 86.4% of participants achieving at least 5% weight reduction [2]. Mounjaro's SURMOUNT-1 trial showed 20.9% average weight loss at the 15mg dose over 72 weeks, with 89.4% achieving at least 5% reduction and 55.5% reaching 20% or greater weight loss [3]. These outcomes position Mounjaro as the more potent option for substantial weight reduction, whilst Wegovy offers proven cardiovascular risk reduction alongside effective weight management.

Side Effect Profiles in Wegovy vs Mounjaro Weight Loss Treatment

Gastrointestinal tolerability represents the primary concern when evaluating Wegovy vs Mounjaro weight loss injections. Both medications commonly cause nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation phases. In clinical trials, approximately 44% of Mounjaro users experienced nausea compared to 44% of Wegovy users at comparable points in treatment, suggesting similar GI side effect burdens [1][2]. Most symptoms resolve within 4-8 weeks as patients physiologically adapt to therapy.

Discontinuation rates due to adverse events provide practical insight into real-world tolerability. SURMOUNT-1 reported 6.2% discontinuation for tirzepatide 15mg due to adverse events, whilst STEP-1 showed 7.0% discontinuation for semaglutide 2.4mg [2][3]. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). Both medications carry MHRA warnings against use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Subject to prescriber approval, careful patient selection and monitoring minimise these risks whilst maximising therapeutic benefit.

Managing Common Adverse Reactions

Practical strategies significantly improve tolerability during Wegovy vs Mounjaro weight loss treatment. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated reduce nausea severity. Taking injections in the evening may help patients sleep through peak nausea periods. If side effects become intolerable, prescribers can slow dose escalation or maintain patients at lower effective doses rather than discontinuing therapy entirely. UK clinical guidelines recommend assessing tolerability at each dose increment before advancing to the next strength, ensuring individualised treatment optimisation.

Dosing Schedules for Wegovy vs Mounjaro Weight Loss Injections

Both Wegovy vs Mounjaro weight loss treatments require once-weekly subcutaneous injection, but their dose escalation schedules differ. Wegovy follows a 16-week titration: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg maintenance. Mounjaro uses a faster 20-week escalation: 2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 4 weeks, 12.5mg for 4 weeks, then 15mg maintenance. Some patients achieve satisfactory results at intermediate doses and remain there long-term under prescriber guidance.

The 1.7mg Wegovy dose mentioned in many UK searches represents the penultimate titration step, not a maintenance dose. Patients typically progress to 2.4mg for maximum efficacy unless tolerability issues necessitate remaining at 1.7mg. This dose still provides significant weight loss—approximately 11-13% average reduction in clinical experience—making it a viable long-term option for those unable to tolerate the highest strength. Mounjaro's intermediate doses (7.5mg, 10mg, 12.5mg) similarly offer substantial benefit for patients who experience side effects at 15mg, with average weight loss of 15-18% at the 10mg maintenance dose [1].

Cost Analysis: Wegovy vs Mounjaro Weight Loss UK Pricing

Pricing represents a crucial factor when choosing between Wegovy vs Mounjaro weight loss treatments in the UK private market. At Cured Pharmacy, Mounjaro starts from £124.99 per 4-week supply, whilst Wegovy begins at £124.99 for equivalent coverage, making Mounjaro the more cost-effective option for most patients. New customers save an additional £20 off their first order using code Weightlossnew, bringing Mounjaro to £124.99 initially. These transparent prices include clinical consultation, prescriber review, and discreet next-day delivery across the UK.

Long-term treatment costs accumulate significantly, as both medications require ongoing use to maintain weight loss. Over a 12-month period, the price difference between treatments can exceed £124.99 annually, making Mounjaro's superior efficacy and lower cost particularly attractive. Neither medication is routinely available on NHS prescription for weight management alone, though patients with type 2 diabetes may access them through specialist diabetes services subject to strict eligibility criteria. Private prescription remains the primary route for most UK patients seeking these treatments for obesity management.

Understanding Total Treatment Investment

When evaluating Wegovy vs Mounjaro weight loss costs, patients should consider the complete financial commitment. Dose escalation phases require purchasing lower-strength pens that cost less than maintenance doses, but the total investment over 6-12 months of therapy typically ranges from £124.99-£124.99 depending on the chosen medication and final maintenance dose. Cured Pharmacy's competitive UK pricing and transparent cost structure help patients budget effectively, with all prices displayed upfront before consultation. Payment plans and subscription options may be available to spread costs across multiple months, making treatment more financially accessible.

Choosing Between Wegovy vs Mounjaro Weight Loss Treatment

Clinical decision-making for Wegovy vs Mounjaro weight loss treatment depends on multiple patient-specific factors. Mounjaro typically suits patients seeking maximum weight reduction, those with pre-diabetes or metabolic syndrome, and individuals prioritising cost-effectiveness. Wegovy remains the preferred choice for patients with established cardiovascular disease (given SELECT trial data), those who prefer a medication with longer UK market presence, or individuals concerned about the novelty of dual-receptor agonists [4]. Both treatments require BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities for UK prescribing.

Contraindications and cautions influence treatment selection significantly. Both medications are contraindicated in pregnancy, personal or family history of medullary thyroid carcinoma, and Multiple Endocrine Neoplasia syndrome type 2. Patients with severe gastrointestinal disease, history of pancreatitis, or diabetic retinopathy require careful prescriber assessment before initiation. The UK-registered clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), conducts thorough assessments to ensure appropriate patient selection and ongoing monitoring. All treatments require online clinical evaluation under 3 minutes, with prescriber approval mandatory before dispensing.

Long-Term Maintenance and Lifestyle Integration

Successful outcomes with Wegovy vs Mounjaro weight loss injections require integration with sustainable lifestyle modifications. Clinical trials demonstrating impressive weight reduction included concurrent dietary counselling and physical activity recommendations. Patients should expect to adopt reduced-calorie eating patterns (typically 500-750 kcal daily deficit) and gradually increase physical activity to 150-300 minutes weekly. Medication facilitates adherence to these changes by reducing appetite and cravings, but does not replace the fundamental energy balance required for weight loss. Upon discontinuation, average weight regain of 5-7% occurs within 12 months, highlighting the need for long-term treatment planning and lifestyle sustainability.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.